Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of intra-arterial cationic liposomal paclitaxel plus systemic therapy in second-line advanced hepatocellular carcinoma
CTR20254675Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and lenvatinib in hepatocellular carcinoma (HCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-limiting toxicity rate, Treatment-emergent adverse events and serious adverse events and 1 more. Started Dec 2025; status: active.
02
Drugs
paclitaxellenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20254675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254675.